LEXARIA BIOSCIENCE CORP. Unrealized Loss on Securities
LEXARIA BIOSCIENCE CORP. (LEXX) reported Unrealized Loss on Securities of $88.29 thousand for the 6-month period ending 2021-02-28, per its 10-Q filed 2021-04-14.
Discontinued › Notes
us-gaap:UnrealizedLossOnSecurities · last filed 2021-04-14
- LEXARIA BIOSCIENCE CORP. unrealized loss on securities for the quarter ending 2021-02-28 was $41.36K, a 5076.72% increase year-over-year.
- LEXARIA BIOSCIENCE CORP. unrealized loss on securities for the quarter ending 2020-11-30 was $46.93K, a 30.94% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. unrealized loss on securities for the quarter ending 2020-08-31 was $0.00, a 100.00% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. unrealized loss on securities for the quarter ending 2020-05-31 was -$21.82K, a 1556.48% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. unrealized loss on securities for fiscal 2019 was $26.97K, a 81.65% increase from fiscal 2018.
- LEXARIA BIOSCIENCE CORP. unrealized loss on securities for fiscal 2018 was $14.85K.
- LEXARIA BIOSCIENCE CORP. unrealized loss on securities for fiscal 2017 was $0.00.
| Period end | Unrealized Loss on Securities 3 month | Unrealized Loss on Securities 6 month | Unrealized Loss on Securities 9 month | Unrealized Loss on Securities 12 month | Unrealized Loss on Securities 12 month as first filed |
|---|---|---|---|---|---|
| 2021-02-28 | $41.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-04-14 | $88.29K 10-Q · filed 2021-04-14 | $88.29K derived: sum of 3 quarters · filed 2021-04-14 | $66.47K derived: sum of 4 quarters · filed 2021-04-14 | |
| 2020-11-30 | $46.93K 10-Q · filed 2021-01-14 | $46.93K derived: sum of 2 quarters · filed 2021-04-14 | $25.11K derived: sum of 3 quarters · filed 2021-04-14 | $25.91K derived: sum of 4 quarters · filed 2021-04-14 | |
| 2020-08-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2021-04-14 | -$21.82K derived: sum of 2 quarters · filed 2021-04-14 | -$21.02K derived: sum of 3 quarters · filed 2021-04-14 | $46.93K 10-Q · filed 2021-04-14 | |
| 2020-05-31 | -$21.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-06-29 | -$21.02K derived: sum of 2 quarters · filed 2020-06-29 | $46.93K 10-Q · filed 2020-06-29 | $58.15K derived: sum of 4 quarters · filed 2020-10-15 | |
| 2020-02-29 | $799.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-04-03 | $68.74K 10-Q · filed 2020-04-03 | $79.97K derived: sum of 3 quarters · filed 2020-10-15 | $81.47K derived: sum of 4 quarters · filed 2020-10-15 | |
| 2019-11-30 | $67.94K 10-Q · filed 2020-01-09 | $79.17K derived: sum of 2 quarters · filed 2020-10-15 | $80.67K derived: sum of 3 quarters · filed 2020-10-15 | $80.67K derived: sum of 4 quarters · filed 2020-10-15 | |
| 2019-08-31 | $11.23K derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-15 | $12.73K derived: sum of 2 quarters · filed 2020-10-15 | $12.73K derived: sum of 3 quarters · filed 2020-10-15 | $26.97K 10-K · filed 2020-10-15 | |
| 2019-05-31 | $1.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-07-08 | $1.50K derived: sum of 2 quarters · filed 2019-07-08 | $15.74K 10-Q · filed 2019-07-08 | $23.21K derived: sum of 4 quarters · filed 2019-11-14 | |
| 2019-02-28 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-04-15 | $14.25K 10-Q · filed 2019-04-15 | $21.71K derived: sum of 3 quarters · filed 2019-11-14 | ||
| 2018-11-30 | $14.25K 10-Q · filed 2019-01-11 | $21.71K derived: sum of 2 quarters · filed 2019-11-14 | |||
| 2018-08-31 | $7.47K derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-14 | $14.85K 10-K · filed 2019-11-14 | $14.25K 10-K · filed 2018-11-14 | ||
| 2018-05-31 | $7.38K 10-Q · filed 2018-07-13 | ||||
| 2017-08-31 | $0.00 10-K · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |